An expert highlights how optimizing CAR T-cell therapy requires simplifying the treatment process, reducing insurance delays, addressing that 40% to 50% of patients may need further therapy, managing ...

An expert discusses that while CAR T-cell therapies carry risks such as cytokine release syndrome and neurotoxicity, advancements in supportive care and monitoring have significantly improved their ...

Allogene Therapeutics halts ALLO-647 trial in large B-cell lymphoma after a patient death raises safety concerns, impacting ...

During a live event, Barbara T. Ma, MD, MS, examined trial data on lifileucel tumor infiltrating lymphocyte therapy in ...

During a live event, Andrew H. Lipsky, MD, and participants debate BTK plus BCL2 inhibitor benefits, barriers, and optimal ...

Cardiff Oncology reveals promising results for onvansertib in treating KRAS- or NRAS-mutated metastatic colorectal cancer, ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

During a live event, Sumanta K. Pal, MD, discussed lenvatinib dosing and tivozanib efficacy for patients with metastatic ...

Trethera Corporation initiates a clinical trial for TRE-515, exploring its potential in oncology and autoimmune diseases ...

Anbogen Therapeutics gains FDA approval for ABT-301, initiating a pivotal trial for metastatic colorectal cancer, targeting ...

An expert discusses the transformative impact of CAR T-cell therapy in relapsed/refractory large B-cell lymphoma, ...